News
Here you will find financial news from APONTIS PHARMA as well as other publications relevant to the capital market.
Latest News
Corporate News
27.06.2024 | EQS-News
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the...
EQS-News: APONTIS PHARMA AG/ Key word(s): Personnel APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the...
Corporate News
04.06.2024 | EQS-News
APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned...
EQS-News: APONTIS PHARMA AG/ Key word(s): Personnel APONTIS PHARMA continues to gear organization towards growth and...
Directors' Dealings
14.05.2024 | EQS-DD
APONTIS PHARMA AG: Thomas Milz, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Directors' Dealings
14.05.2024 | EQS-DD
APONTIS PHARMA AG: be executive GmbH, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Directors' Dealings
13.05.2024 | EQS-DD
APONTIS PHARMA AG: Thomas Zimmermann, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Directors' Dealings
13.05.2024 | EQS-DD
APONTIS PHARMA AG: Thomas Zimmermann, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Directors' Dealings
13.05.2024 | EQS-DD
APONTIS PHARMA AG: Thomas Zimmermann, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Directors' Dealings
13.05.2024 | EQS-DD
APONTIS PHARMA AG: Thomas Zimmermann, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Directors' Dealings
13.05.2024 | EQS-DD
APONTIS PHARMA AG: Thomas Zimmermann, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Corporate News
08.05.2024 | EQS-News
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and...
EQS-News: APONTIS PHARMA AG/ Key word(s): Quarterly/ Interim Statement/Quarter Results APONTIS PHARMA starts...
Corporate News
05.04.2024 | EQS-News
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma...
EQS-News: APONTIS PHARMA AG/ Key word(s): Change in Forecast/Alliance APONTIS PHARMA enters five-year distribution...
Ad-hoc News
05.04.2024 | EQS-Ad-hoc
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement...
APONTIS PHARMA AG/ Key word(s): Forecast/Change in Forecast APONTIS PHARMA AG raises forecast after entering...
Corporate News
28.03.2024 | EQS-News
APONTIS PHARMA expects profitable growth again in 2024
EQS-News: APONTIS PHARMA AG/ Key word(s): Annual Results/Annual Report APONTIS PHARMA expects profitable growth...
Corporate News
06.02.2024 | EQS-News
APONTIS PHARMA successfully completes performance and efficiency improvement program
EQS-News: APONTIS PHARMA AG/ Key word(s): Strategic Company Decision/Restructure of Company APONTIS PHARMA...
Corporate News
09.11.2023 | EQS-News
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures...
EQS-News: APONTIS PHARMA AG/ Key word(s): Quarterly/ Interim Statement/9 Month figures APONTIS PHARMA presents...
Ad-hoc News
08.11.2023 | EQS-Ad-hoc
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program
APONTIS PHARMA AG/ Key word(s): Strategic Company Decision/Restructure of Company APONTIS PHARMA AG with new...
Corporate News
10.08.2023 | EQS-News
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline
EQS-News: APONTIS PHARMA AG/ Key word(s): Half Year Results/Half Year Report APONTIS PHARMA confirms preliminary...
Ad-hoc News
31.07.2023 | EQS-Ad-hoc
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024
APONTIS PHARMA AG/ Key word(s): Contract APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued...
Corporate News
27.07.2023 | EQS-News
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 –...
EQS-News: APONTIS PHARMA AG/ Key word(s): Change in Forecast/Profit Warning APONTIS PHARMA AG withdraws forecast for...
Ad-hoc News
27.07.2023 | EQS-Ad-hoc
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026
APONTIS PHARMA AG/ Key word(s): Change in Forecast/Profit Warning APONTIS PHARMA AG withdraws forecast for fiscal...
Corporate News
10.07.2023 | EQS-News
APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons - Bruno Wohlschlegel takes over as...
EQS-News: APONTIS PHARMA AG/ Key word(s): Personnel APONTIS PHARMA: CEO Karlheinz Gast resigns for personal reasons-...
Ad-hoc News
10.07.2023 | EQS-Ad-hoc
APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal reasons
APONTIS PHARMA AG/ Key word(s): Personnel APONTIS PHARMA AG: CEO Karlheinz Gast resigns from office for personal...
Corporate News
29.06.2023 | EQS-News
APONTIS PHARMA launches Single Pill Finder and distribution of Single Pill Rosazimib - First of...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA launches Single Pill Finder and distribution...
Corporate News
09.05.2023 | EQS-News
APONTIS PHARMA in Q1 2023 records decline in sales and earnings as expected – 2023 as a transition...
EQS-News: APONTIS PHARMA AG/ Key word(s): Quarterly/ Interim Statement APONTIS PHARMA in Q1 2023 records decline in...
Corporate News
08.05.2023 | EQS-News
APONTIS PHARMA: Keeping up high pace in expansion of Single Pill portfolio - New development...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA: Keeping up high pace in expansion of Single...
Directors' Dealings
05.05.2023 | EQS-DD
APONTIS PHARMA AG: Silke Reineke, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Directors' Dealings
05.05.2023 | EQS-DD
APONTIS PHARMA AG: Thomas Milz, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons...
Ad-hoc News
02.05.2023 | EQS-Ad-hoc
APONTIS PHARMA AG adjusts forecast for fiscal year 2023
APONTIS PHARMA AG/ Key word(s): Forecast/Change in Forecast APONTIS PHARMA AG adjusts forecast for fiscal year 2023...
Corporate News
27.04.2023 | EQS-News
APONTIS PHARMA with first in-licensing of a Single Pill with two active ingredients for the primary...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA with first in-licensing of a Single Pill...
Corporate News
12.04.2023 | EQS-News
APONTIS PHARMA: New development partnership with Midas Pharma – Expansion of Single Pill portfolio...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA: New development partnership with Midas...
Corporate News
09.03.2023 | EQS-News
APONTIS PHARMA with successful financial year 2022: Revenue and EBITDA forecast slightly exceeded...
EQS-News: APONTIS PHARMA AG/ Key word(s): Preliminary Results/Annual Results APONTIS PHARMA with successful...
Corporate News
14.02.2023 | EQS-News
APONTIS PHARMA accelerates expansion of Single Pill portfolio with second of three in-licensing...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA accelerates expansion of Single Pill...
Corporate News
31.01.2023 | EQS-News
APONTIS PHARMA extends portfolio for the treatment of hypertension and hyperlipidemia by...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA extends portfolio for the treatment of...
Corporate News
29.11.2022 | EQS-News
APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows...
EQS-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA: Number of announced market launches...
Corporate News
10.11.2022 | EQS-News
APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill...
EQS-News: APONTIS PHARMA AG/ Key word(s): 9 Month figures/Quarterly/ Interim Statement APONTIS PHARMA confirms 2022...
Corporate News
20.09.2022 | EQS-News
APONTIS PHARMA announces cooperation to launch new Single Pill in Germany
EQS-News: APONTIS PHARMA AG/ Key word(s): Alliance/Product Launch APONTIS PHARMA announces cooperation to launch new...
Corporate News
01.09.2022 | DGAP-News
APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill
DGAP-News: APONTIS PHARMA AG/ Key word(s): Scientific publication APONTIS PHARMA: SECURE study and START study...
Corporate News
11.08.2022 | DGAP-News
APONTIS PHARMA expands profitable positioning in first half of 2022 – full-year forecast confirmed
DGAP-News: APONTIS PHARMA AG/ Key word(s): Half Year Report/Half Year Results APONTIS PHARMA expands profitable...
Corporate News
19.07.2022 | DGAP-News
APONTIS PHARMA and Midas Pharma agree on further development partnership for the market launch of a...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Alliance/Market launch APONTIS PHARMA and Midas Pharma agree on further...
Corporate News
06.07.2022 | DGAP-News
APONTIS PHARMA rolls out new Single Pill for secondary prophylaxis
DGAP-News: APONTIS PHARMA AG/ Key word(s): Market launch APONTIS PHARMA rolls out new Single Pill for secondary...
Corporate News
23.06.2022 | DGAP-News
APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052
DGAP-News: APONTIS PHARMA AG/ Key word(s): Share Buyback APONTIS PHARMA AG: Notice according to Article 2 paragraph...
Corporate News
25.05.2022 | DGAP-News
APONTIS PHARMA launches two new single pills - medium-term revenue potential of EUR 8.2 million
DGAP-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA launches two new single pills- medium-term...
Corporate News
12.05.2022 | DGAP-News
APONTIS PHARMA holds Annual General Meeting 2022 - shareholders approve all agenda items with large...
DGAP-News: APONTIS PHARMA AG/ Key word(s): AGM/EGM APONTIS PHARMA holds Annual General Meeting 2022- shareholders...
Corporate News
10.05.2022 | DGAP-News
APONTIS PHARMA continues strong profitable growth in Q1 2022
DGAP-News: APONTIS PHARMA AG/ Key word(s): Quarterly/ Interim Statement APONTIS PHARMA continues strong profitable...
Corporate News
05.05.2022 | DGAP-News
APONTIS PHARMA and Develco Pharma enter development partnership for launch of two Single Pills with...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Product Launch APONTIS PHARMA and Develco Pharma enter development...
Corporate News
20.04.2022 | DGAP-News
APONTIS PHARMA: START study published in scientific journal - Cost reduction in the treatment of...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Scientific publication APONTIS PHARMA: START study published in...
Corporate News
16.03.2022 | DGAP-News
APONTIS PHARMA: START study published in scientific journal - Lower incidence of cardiovascular...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Scientific publication 16.03.2022/ 07:30 The issuer is solely responsible...
Corporate News
15.03.2022 | DGAP-News
APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052
DGAP-News: APONTIS PHARMA AG/ Key word(s): Share Buyback 15.03.2022/ 07:30 The issuer is solely responsible for the...
Corporate News
08.03.2022 | DGAP-News
APONTIS PHARMA and AstraZeneca extend strategic sales cooperation
DGAP-News: APONTIS PHARMA AG/ Key word(s): Alliance 08.03.2022/ 07:30 The issuer is solely responsible for the...
Corporate News
03.03.2022 | DGAP-News
APONTIS PHARMA reports successful financial year 2021 - Single Pills as growth driver
DGAP-News: APONTIS PHARMA AG/ Key word(s): Preliminary Results/Annual Results 03.03.2022/ 07:30 The issuer is solely...
Corporate News
16.12.2021 | DGAP-News
APONTIS PHARMA strengthens management for future growth: Thomas Zimmermann appointed new CFO
DGAP-News: APONTIS PHARMA AG/ Key word(s): Personnel 16.12.2021/ 07:30 The issuer is solely responsible for the...
Corporate News
14.12.2021 | DGAP-News
APONTIS PHARMA and Midas Pharma announce development partnership to launch Single Pill with...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Product Launch/Alliance 14.12.2021/ 07:30 The issuer is solely...
Corporate News
18.11.2021 | DGAP-News
APONTIS PHARMA grows significantly faster than the overall market in the nine-month period 2021 -...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Quarterly/ Interim Statement/9 Month figures 18.11.2021/ 07:30 The issuer...
Corporate News
26.10.2021 | DGAP-News
APONTIS PHARMA announces market launch of new Single Pill
DGAP-News: APONTIS PHARMA AG/ Key word(s): Product Launch 26.10.2021/ 07:30 The issuer is solely responsible for the...
Corporate News
14.09.2021 | DGAP-News
APONTIS PHARMA announces launch of new Single Pill for more efficient treatment of hypertension and...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Product Launch 14.09.2021/ 07:30 The issuer is solely responsible for the...
Corporate News
11.08.2021 | DGAP-News
APONTIS PHARMA builds on strong position and profitability in first half of 2021 - preliminary...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Half Year Results/Half Year Report 11.08.2021/ 07:30 The issuer is solely...
Corporate News
28.07.2021 | DGAP-News
APONTIS PHARMA reports accelerated growth in first half of 2021 - Single Pill revenues +83% to EUR...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Preliminary Results/Half Year Results 28.07.2021/ 07:30 The issuer is...
Corporate News
12.07.2021 | DGAP-News
APONTIS PHARMA marks further success in the roll-out of Single Pill therapy
DGAP-News: APONTIS PHARMA AG/ Key word(s): Alliance 12.07.2021/ 07:30 The issuer is solely responsible for the...
Corporate News
18.06.2021 | DGAP-News
APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Research Update 18.06.2021/ 07:30 The issuer is solely responsible for...
Corporate News
10.06.2021 | DGAP-News
APONTIS PHARMA AG: Post-Stabilisation disclosure - Partial exercise of the Greenshoe Option
DGAP-News: APONTIS PHARMA AG/ Key word(s): Miscellaneous 10.06.2021/ 21:23 The issuer is solely responsible for the...
Corporate News
10.06.2021 | DGAP-News
APONTIS PHARMA AG: Notification on the implementation of stabilization measures
DGAP-News: APONTIS PHARMA AG/ Key word(s): Miscellaneous 10.06.2021/ 21:20 The issuer is solely responsible for the...
Corporate News
28.05.2021 | DGAP-News
APONTIS PHARMA AG: Notification on the implementation of stabilization measures
DGAP-News: APONTIS PHARMA AG/ Key word(s): Miscellaneous 28.05.2021/ 20:05 The issuer is solely responsible for the...
Corporate News
20.05.2021 | DGAP-News
APONTIS PHARMA AG Trading Update: Strong revenues and earnings growth with Single Pills continues...
DGAP-News: APONTIS PHARMA AG/ Key word(s): Quarterly/ Interim Statement 20.05.2021/ 07:30 The issuer is solely...
Corporate News
19.05.2021 | DGAP-News
APONTIS PHARMA AG: Notification on the implementation of stabilization measures
DGAP-News: APONTIS PHARMA AG/ Key word(s): Miscellaneous 19.05.2021/ 20:23 The issuer is solely responsible for the...
Corporate News
14.05.2021 | EQS-News
Apontis Pharma (APPH): Initiation - A phoenix rises
Edison Investment Research Limited 14-May-2021/ 07:00 GMT/BST London, UK, 14 May 2021 Apontis...
Corporate News
06.05.2021 | DGAP-News
APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share
DGAP-News: APONTIS PHARMA AG/ Key word(s): IPO 06.05.2021/ 20:09 The issuer is solely responsible for the content of...
Ad-hoc News
06.05.2021 | DGAP-Ad-hoc
APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share
APONTIS PHARMA AG/ Key word(s): IPO APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share...
Corporate News
29.04.2021 | DGAP-News
APONTIS PHARMA AG sets price range for planned IPO between EUR 18.50 and EUR 24.50 per share
DGAP-News: APONTIS PHARMA AG/ Key word(s): IPO 29.04.2021/ 08:30 The issuer is solely responsible for the content of...
Corporate News
21.04.2021 | DGAP-News
APONTIS PHARMA plans initial public offering
DGAP-News: APONTIS PHARMA AG/ Key word(s): IPO 21.04.2021/ 08:30 The issuer is solely responsible for the content of...
Sven Pauly
Thank you very much,
we have received your message
and will contact you shortly!
we have received your message
and will contact you shortly!